PCRC Home
General Clinical Research Center
Clinical Care
PCRC Faculty/Staff
Current Research
Contact Information
Directions

Psychiatric Clinical Research Center
Current Research

Inclusion/Exclusion Criteria:

• Eligible patients include those with a primary diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, major depression, or other psychotic disorders
• Patients must be at least 18 years old
• Voluntary admission
• Legally and clinically competent to give informed consent for research
• Without significant medical illness

An Investigational Drug vs. Placebo in the Maintenance Treatment of Bipolar I Disorder, Manic or Mixed Episode.
Investigator: Philip Janicak, M.D.

Investigational New Drug Versus Perphenazine in the Treatment of Patients with Treatment-Resistant Schizophrenia
Investigator: Philip Janicak, M.D.

Double-blind Placebo-controlled trial of a Vasopressin antagonist in the Treatment of Hyponatremia. Investigator: Morris Goldman, M.D.

The Efficacy and Safety of Flexible Dose Ranges of an Investigational Drug vs Placebo in the Treatment of Manic Episodes associated with Bipolar 1 Disorder
Investigator: Philip Janicak, M.D.

Genetic Variants in Schizophrenia and Bipolar Disorder: A Pilot Study.
Investigator: Rajiv Sharma, M.D.

Olanzapine versus Haloperidol: Effect on Primary Polydipsia and Stereotypic Behaviors in Chronic Schizophrenic Patients
Investigator: Morris Goldman, M.D.

Repetitive Transcranial Magnetic Stimulation vs. ECT for Depression
Investigator: Philip Janicak, M.D.

Serotonin Receptors and Protein Kinase C in Depression
Investigator: Ghanshyam Pandey, Ph.D.

Treatment of Major Depressive Disorder with Psychotic Features with an Investigational Drug as Monotherapy; an Investigational Drug and Sertraline; or Haloperidol and Sertraline.
Investigator: Philip Janicak, M.D.